| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | ORCAM |
| Uniprot No | A0A7G5CF76 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-155aa |
| 氨基酸序列 | MAEGLSDERIVELKEAFNLFDKDGDGFITTSELGIVMTSLNQNPSDGELQDMINEVDADGNGTIDFNEFLRMMARKAKETDIDEELRQAFKVFDRDGNGFISADELRQVMSNLGEKLTDDEVDEMIKEADVDGDGQVNYEEFVKLMTTRQTDASN |
| 预测分子量 | 17,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是基于学术文献的参考示例(注：ORCAM重组蛋白可能为特定领域术语，以下为模拟格式，实际文献需根据具体研究方向检索)：
1. **文献名称**: "Expression and functional analysis of ORCAM recombinant protein in neural adhesion"
**作者**: Smith A, et al.
**摘要**: 研究通过大肠杆菌系统表达ORCAM重组蛋白，验证其在神经元细胞黏附中的作用，证实其通过调控突触蛋白相互作用促进神经发育。
2. **文献名称**: "ORCAM recombinant protein enhances osteoclast differentiation via RANKL signaling pathway"
**作者**: Chen L, et al.
**摘要**: 利用哺乳动物细胞体系成功纯化ORCAM重组蛋白，发现其通过激活RANKL通路促进破骨细胞分化，为骨代谢疾病治疗提供潜在靶点。
3. **文献名称**: "Structural characterization of ORCAM recombinant protein using cryo-EM"
**作者**: Tanaka K, et al.
**摘要**: 通过冷冻电镜解析ORCAM重组蛋白的三维结构，揭示其与配体结合的活性位点，为基于结构的药物设计奠定基础。
4. **文献名称**: "Application of ORCAM recombinant protein in cancer immunotherapy"
**作者**: Wang Y, et al.
**摘要**: 在小鼠模型中验证ORCAM重组蛋白作为肿瘤抗原递呈载体的潜力，显示其可显著增强T细胞抗肿瘤免疫应答。
---
**注意**：若“ORCAM”为笔误或特定缩写，建议结合具体研究领域(如神经科学、免疫学等)进一步检索。例如，若指“ORC”(起源识别复合物)，可参考复制起始相关重组蛋白研究文献。
ORCAM recombinant proteins are engineered biological molecules designed to support a wide range of research, therapeutic, and diagnostic applications. These proteins are produced using advanced recombinant DNA technology, where specific genes encoding target proteins are cloned into host cells—often mammalian, bacterial, or insect systems—to enable large-scale expression. ORCAM emphasizes precision in protein design, ensuring proper folding, post-translational modifications, and functional activity, which are critical for mimicking native human proteins.
The development of ORCAM recombinant proteins is driven by the growing demand for high-quality, consistent reagents in biomedical research and drug discovery. Traditional protein purification from natural sources often faces challenges like low yield, batch-to-batch variability, and contamination risks. ORCAM addresses these limitations by leveraging controlled expression systems, enabling scalable production with enhanced purity and reproducibility. Their portfolio includes cytokines, growth factors, enzymes, and antibodies, tailored for applications such as cell culture studies, target validation, and assay development.
A key focus of ORCAM is optimizing protein stability and bioactivity. Techniques like site-directed mutagenesis or fusion tags are employed to improve solubility, extend half-life, or facilitate detection. Rigorous quality control measures, including SDS-PAGE, mass spectrometry, and functional assays, ensure each batch meets stringent standards. Additionally, ORCAM proteins are often lyophilized or formulated in buffer systems to maintain long-term stability.
These proteins play a pivotal role in accelerating therapeutic development, particularly in oncology, immunology, and regenerative medicine. Researchers rely on ORCAM reagents to study disease mechanisms, screen drug candidates, and engineer biologics. By bridging the gap between basic research and clinical translation, ORCAM recombinant proteins have become indispensable tools in modern life sciences and biopharmaceutical industries.
×
